DEVELOPMENT OF A SPIKE-IN FLOW-CYTOMETRY METHOD FOR THE QUANTITATION OF FETAL HEMOGLOBIN (HBF) IN INDIVIDUAL RED BLOOD CELLS OF SICKLE CELL DISEASE (SCD) PATIENTS

Abstract

HbF is the most relevant modulator of the severity of SCD, inhibiting the polymerization of the mutant sickle hemoglobin (HbS). Despite its clinical relevance, a straightforward method to quantify and identify protective levels of HbF in individual red blood cells (RBCs) is still lacking. Here, we sought to develop a fluorescent-labeled RBC “Spike-In”(Spk) control (Ctr), to be mixed with patient samples, to serve as an internal reference in a novel quantitative flow-cytometry method. The Spk-Ctr was generated by mixing equal numbers of CFSE-labeled and fixed HbF Neg adult and HbF Pos cord blood (CB) RBCs, whose mean corpuscular HbF (MCHbF) mass was pre-calculated, based on the %HbF (HPLC-derived) and the MCH (hematology analyzer), using the formula: MCHbF=(%HbFxMCH)/100. Spk-Ctr was mixed with a similarly-fixed Test Sample, composed of 10% HbF Pos (prepared with the same RBCs as the Spk-Ctr), permeabilized, stained with an anti-HbF PE conjugate, and acquired by a flow cytometer. The anti-HbF PE Median Intensity Fluorescence (MIF) was obtained for gated HbF Pos RBCs in both the Ctr CFSE Pos and Test CFSE Neg gated populations. A conversion factor (CF) was calculated by dividing the pre-calculated MCHbF by the MIF obtained for HbF Pos RBCs from the CFSE Pos Spk-Ctr. By multiplying the anti-HbF PE fluorescence intensity of each RBC in the test sample by the CF, an absolute HbF/RBC values (in pg of HbF per RBC) can be obtained, which can be used to generate a distribution histogram to calculate the percentage of RBCs above a protective HbF/RBC threshold. The Ctr CB used had 73.2% HbF and a MCH of 36.4pg, resulting in a MCHbF of 26.64pg. The anti-HbF PE MIF of the Spk-Ctr HbF Pos RBCs was 25,166a.u. (arbitrary units), resulting in a CF of 0.001058. The anti-HbF PE MIF of the HbF Pos RBCs of the Test Sample was 24,146a.u., leading to an estimated MCHbF of 25.56pg; a deviation of only 4% from the expected (known) MCHbF. In contrast, when samples were permeabilized and stained in separate tubes, this variation was 27%. Recently, a work described a laborious method requiring a standard curve, generated with rare samples from subjects with hereditary persistence of HbF, and calibration beads. This method correct only for experimental variations arising from flow-cytometry acquisition and bath-to-bath antibody affinity/fluorescence differences, but not from experimental variability associated with sample handling of the test patient samples and those used in the standard curve. Our method eliminates the complexity associated with the use of a cumbersome standard curve, as the Spike-In Ctr and patient cells are subjected to the exact same procedures (in the same tube). Thus, experimental variability (derived from differences in, pipetting, incubation time, temperature, affinity/fluorescence of antibody batches, instrument or acquisition settings, etc.) is not expected to interfere with the quantitation. Once fully developed and validated, our method may serve as an auxiliary tool for the clinical management of SCD patients, contributing to the prediction of complications (allowing preventive measures to be adopted), or allowing the monitoring of the response to therapeutic approaches based on the induction of HbF (including hydroxyurea).